profit from every R$100 of sales.
R$0R$100
Diagnósticos da América
R$3.63-3.20% today
+179.2% in 1 year
1-year low R$1.301-year high R$5.64
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Diagnósticos da América sold, what it kept, and what it did with the cash.
Sales went from R$13.1 billion in 2022 to R$11.2 billion in 2025, with -R$1.15 billion of profit last year.
SalesProfit
Diagnósticos da América vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from R$100 of sales | Sales growth a year | Price per R$1 of profit |
|---|---|---|---|
| Diagnósticos da América | No profit yet | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
AI analysis
An AI analyst reads Diagnósticos da América's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13,129 | 14,252 | 15,322 | 11,170 | |
| 3,798 | 3,887 | 4,193 | 3,393 | |
| 1,048 | 912 | 1,007 | 1,012 | |
| 2,211 | 2,091 | 1,988 | 2,039 | |
| -387 | -1,166 | -1,199 | -1,152 | |
| -0.69 | -1.56 | -0.96 | -0.92 | |
| 28.9% | 27.3% | 27.4% | 30.4% | |
| 8.0% | 6.4% | 6.6% | 9.1% | |
| -2.9% | -8.2% | -7.8% | -10.3% |
Balance sheet
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 26,844 | 26,213 | 26,458 | 18,562 |
| Cash | 1,285 | 1,585 | 1,743 | 2,665 |
| Total debt | 13,904 | 13,295 | 12,993 | 8,842 |
| Total liabilities | 19,755 | 18,879 | 18,523 | 11,669 |
| 7,079 | 7,330 | 7,926 | 6,865 | |
| 582 | 786 | 1,288 | 1,250 | |
| 3.5% | 2.5% | 2.0% | 3.8% | |
| -5.5% | -15.9% | -15.1% | -16.8% |
Cash flow
| In millions of BRL | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -964 | 28 | -36 | |
| 1,136 | 811 | 538 | 290 | |
| -1,165 | -1,775 | -511 | -327 | |
| Dividends paid | 159 | – | 10 | 5 |
| 0 | 108 | 0 | – | |
| 23 | 67 | -47 | 21 |
Valuation
- –
- –
- –
- 0.5×
- 0.4×
- –
- 5.3×
- -7.2%
- -25.4%
- 0.1%
Profitability
- 30.4%
- 9.1%
- -10.3%
- –
- 3.8%
- 3.0%
- –
- –
- –
- –
Growth
- −5.2%
- –
- –
- –
- +29.0%
Financial health
- 3.0×
- 1.29
- –
- 0.6×
- 1.24
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 43%of 952
Top 50%of 883
Bottom 9%of 870
Bottom 14%of 985
0.1%of the share price, paid each year
On $1,000 invested$1a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
51No pass
Philip Fisher
24No pass
Peter Lynch
16No pass
Joel Greenblatt
29No pass
Charlie Munger
10No pass
Terry Smith
7No pass
Questions about Diagnósticos da América
Is Diagnósticos da América a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Diagnósticos da América AI analysis
What does Diagnósticos da América do?
Diagnósticos da América S.A., together with its subsidiaries, provides diagnostic and hospital services in Brazil and Argentina. The company operates through Hospitals and Oncology; Diagnostics - National Operations; and Diagnostics - International Operations segments. It is in Diagnostics & Research, based in São Paulo, SP, Brazil, with 26,255 employees.
Does Diagnósticos da América pay a dividend?
Yes. At today's price the dividend is 0.1% a year. In 2025 it paid out R$5.02 million in dividends.
Is Diagnósticos da América stock halal?
No. Diagnósticos da América does not pass our halal screen: its debt is 195% of its market value, at or above the 33% limit. How we check
How has Diagnósticos da América stock done over the past year?
Up 179.2% over the past twelve months, to R$3.63. It traded between R$1.30 and R$5.64 and is 35.6% below its high.
Who are Diagnósticos da América's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Diagnósticos da América's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.